Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC
Sponsor: National Cancer Institute (NCI)
A observational or N/A phase clinical study on Recurrent Lung Non-Small Cell Carcinoma and Stage IV Lung Non-Small Cell Cancer AJCC v7, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 50 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To compare the progression-free survival (PFS) associated with patients treated with erlotinib (erlotinib hydrochloride) versus (vs) erlotinib plus cabozantinib (cabozantinib-s-malate). II. To compare the PFS associated with patients treated with erlotinib vs cabozantinib. SECONDARY OBJECTIVES: I. To evaluate overall survival in the three treatment arms. II. To evaluate best objective response rate in the three treatment arms. III. To define the toxicity associated with each regimen. IV. To conduct correlative science studies that will help to select predictive biomarkers of response to therapy, including mesenchymal-epidermal transition (MET) expression and potentially other tissue biomarkers, plasma biomarkers, and bone scans. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM A (erlotinib): Patients receive erlotinib orally (PO) daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ARM B (cabozantinib): Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ARM C (erlotinib+cabozantinib): Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ARM Z: Patients achieving disease progression...
PRIMARY OBJECTIVES:
I. To compare the progression-free survival (PFS) associated with patients treated with erlotinib (erlotinib hydrochloride) versus (vs) erlotinib plus cabozantinib (cabozantinib-s-malate).
II. To compare the PFS associated with patients treated with erlotinib vs cabozantinib.
SECONDARY OBJECTIVES:
I. To evaluate overall survival in the three treatment arms. II. To evaluate best objective response rate in the three treatment arms. III. To define the toxicity associated with each regimen. IV. To conduct correlative science studies that will help to select predictive biomarkers of response to therapy, including mesenchymal-epidermal transition (MET) expression and potentially other tissue biomarkers, plasma biomarkers, and bone scans.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM A (erlotinib): Patients receive erlotinib orally (PO) daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM B (cabozantinib): Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM C (erlotinib+cabozantinib): Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM Z: Patients achieving disease progression in Arm A or Arm B may receive erlotinib and cabozantinib as patients in Arm C. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Status Flow
Change History
50 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2 → None
-
Dec 2025 — May 2026 [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 45 earlier versions
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .